Reata reinforces management team
This article was originally published in Scrip
Reata Pharmaceuticals has expanded its management team with the appointment of four executives: Dr Paul Audhya, who has previously led drug development at Johnson & Johnson, Bristol-Myers Squibb and Abbott Laboratories, joins as vice-president of development and chief medical officer; Dr Hilary Malone joins as vice-president and chief regulatory and compliance officer from Pfizer, where she was senior vice-president and head of worldwide regulatory strategy; Sean Nolan, who joins Reata as vice-president and chief commercial officer, was previously president of the US entity that emerged following Lundbeck's acquisition of Ovation Pharmaceuticals; and Jim Rouse, most recently executive director of information technology at PharmaNet Development Group, joins as chief information officer. In addition, the company has elected Nancy Wysenski, executive vice-president and chief commercial officer of Vertex Pharmaceuticals, to its board of directors.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.